Form 4: Provectus Biopharmaceuticals Director Acquires 775,082 Stock Options

Director John Lacey III acquired 775,082 stock options in Provectus Biopharmaceuticals on December 2, 2024.

Summary

• John Lacey III, a director at Provectus Biopharmaceuticals, acquired 775,082 stock options on December 2, 2024.
• The stock options have an exercise price of $0.2862 per share.
• The options are exercisable starting December 2, 2024, and expire on December 2, 2034.
• The acquisition was a direct transaction.

Sentiment

Score: 6

Explanation: The document is a routine filing and does not contain any information that would significantly impact the sentiment. The acquisition of options by a director is a neutral to slightly positive event.

Positives

• The acquisition of stock options by a director could be seen as a positive sign of confidence in the company's future.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure required by the SEC.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies, particularly in the biotechnology sector, as a way to align their interests with those of shareholders.
• The exercise price of $0.2862 is specific to Provectus Biopharmaceuticals and would need to be compared to other similar companies to assess its relative value.
• The 10-year term of the options is also typical for such grants.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, director, beneficial ownership, Provectus Biopharmaceuticals, PVCT, insider trading